John Öhd is to become Karolinska Institute's chief scientific officer on the back of 13 years of biotech industry expertise.
Karolinska Development, the investment arm of Karolinska Institute, yesterday hired John Öhd as chief scientific officer.
Öhd will start on June 1, 2020 on a part-time basis in order to continue his work as CEO of sickle cell disease therapy developer Modus Therapeutics, a spinout of Karolinska Institute and Uppsala University.
He will report directly to chief executive Viktor Drvota and will form part of Karolinska’s management team. Öhd arrives with more than 13 years of biotech industry experience.
Before joining Modus, he spent more than four years with oncological drug developer Medivir, initially as director for clinical R&D before moving to chief medical officer in 2017.
He was senior director for experimental medicine at speciality biopharmaceutical firm Shire from 2012 until 2014, after five years with pharmaceutical firm AstraZeneca, latterly as a group director, between 2007 and 2014.
Drvota said: “We are delighted to welcome John Öhd to the position of CSO. His solid scientific and medical background will strengthen Karolinska Development in the active work with our portfolio companies and in the evaluation of potential new investments.”
– Image courtesy of LinkedIn
